



Number at risk

--- RT (-)	40	30	21	17	13	11	8
— RT (+)	22	18	18	17	14	11	9

Supplementary Figure 2. Kaplan-Meier estimates of progression-free survival defined as time from atezolizumab plus bevacizumab initiation to disease progression (Vp1-3). HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; RT, radiation therapy.